Skip to main content

In Brief This Week: GE Healthcare; BioServe; DNA Genotek

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare has opened a new medical technology manufacturing facility in Cardiff, Wales. The $15 million facility will produce nearly 2,000 life sciences products used in the pharmaceutical, food, and environmental industries. GE said that it already employs more than 400 people at the facility.

BioServe said this week that it has received accreditation from India's National Board of Testing and Calibration of Laboratories for detecting genetically modified materials in raw and processed foods. The firm announced the accreditation in conjunction with the launch of a line of PCR-based tests for detecting genetically modified organisms.

DNA Genotek said that the South African Tuberculosis Vaccine Initiative has chosen to use the firm's Oragene DNA Self-Collection Kits to obtain samples for a study aimed at identifying host correlates of protection against TB, following BCG vaccination.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.